{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T11:42:11Z","timestamp":1776944531803,"version":"3.51.4"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T00:00:00Z","timestamp":1731024000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T00:00:00Z","timestamp":1731024000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2025,2,10]]},"DOI":"10.1038\/s41388-024-03215-w","type":"journal-article","created":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T14:34:08Z","timestamp":1731076448000},"page":"241-254","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Targeting DDX3X eliminates leukemia stem cells in chronic myeloid leukemia by blocking NT5DC2 mRNA translation"],"prefix":"10.1038","volume":"44","author":[{"given":"Chen","family":"Duan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoying","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Waiyi","family":"Zou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qi","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fen","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingxuan","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7569-5546","authenticated-orcid":false,"given":"Yanli","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,11,8]]},"reference":[{"key":"3215_CR1","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1016\/S0140-6736(21)01204-6","volume":"398","author":"J Cortes","year":"2021","unstructured":"Cortes J, Pavlovsky C, Saussele S. Chronic myeloid leukaemia. Lancet. 2021;398:1914\u201326.","journal-title":"Lancet"},{"key":"3215_CR2","doi-asserted-by":"publisher","first-page":"2567.","DOI":"10.3390\/jcm13092567","volume":"13","author":"G Bourne","year":"2024","unstructured":"Bourne G, Bhatia R, Jamy O. Treatment-free remission in chronic myeloid leukemia. J Clin Med. 2024;13:2567.","journal-title":"J Clin Med"},{"key":"3215_CR3","doi-asserted-by":"publisher","first-page":"5822.","DOI":"10.3390\/cancers13225822","volume":"13","author":"K Ito","year":"2021","unstructured":"Ito K, Ito K. Leukemia stem cells as a potential target to achieve therapy-free remission in chronic myeloid leukemia. Cancers. 2021;13:5822.","journal-title":"Cancers"},{"key":"3215_CR4","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s13238-015-0143-7","volume":"6","author":"H Zhou","year":"2015","unstructured":"Zhou H, Xu R. Leukemia stem cells: the root of chronic myeloid leukemia. Protein Cell. 2015;6:403\u201312.","journal-title":"Protein Cell"},{"key":"3215_CR5","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1172\/JCI35721","volume":"121","author":"AS Corbin","year":"2011","unstructured":"Corbin AS, Agarwal A, Loriaux M, Cortes J, Deininger MW, Druker BJ. Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. J Clin Invest. 2011;121:396\u2013409.","journal-title":"J Clin Invest"},{"key":"3215_CR6","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1182\/blood-2010-12-326843","volume":"119","author":"A Hamilton","year":"2012","unstructured":"Hamilton A, Helgason GV, Schemionek M, Zhang B, Myssina S, Allan EK, et al. Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival. Blood. 2012;119:1501\u201310.","journal-title":"Blood"},{"key":"3215_CR7","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1038\/s41375-019-0490-0","volume":"33","author":"M Houshmand","year":"2019","unstructured":"Houshmand M, Simonetti G, Circosta P, Gaidano V, Cignetti A, Martinelli G, et al. Chronic myeloid leukemia stem cells. Leukemia. 2019;33:1543\u201356.","journal-title":"Leukemia"},{"key":"3215_CR8","doi-asserted-by":"publisher","first-page":"3657","DOI":"10.1182\/blood-2011-02-335497","volume":"118","author":"JC Chomel","year":"2011","unstructured":"Chomel JC, Bonnet ML, Sorel N, Bertrand A, Meunier MC, Fichelson S, et al. Leukemic stem cell persistence in chronic myeloid leukemia patients with sustained undetectable molecular residual disease. Blood. 2011;118:3657\u201360.","journal-title":"Blood"},{"key":"3215_CR9","doi-asserted-by":"publisher","first-page":"5565","DOI":"10.1182\/blood-2010-12-327437","volume":"118","author":"S Chu","year":"2011","unstructured":"Chu S, McDonald T, Lin A, Chakraborty S, Huang Q, Snyder DS, et al. Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment. Blood. 2011;118:5565\u201372.","journal-title":"Blood"},{"key":"3215_CR10","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/j.ccr.2007.11.003","volume":"12","author":"C Zhao","year":"2007","unstructured":"Zhao C, Blum J, Chen A, Kwon HY, Jung SH, Cook JM, et al. Loss of \u03b2-catenin impairs the renewal of normal and CML stem cells in vivo. Cancer Cell. 2007;12:528\u201341.","journal-title":"Cancer Cell"},{"key":"3215_CR11","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1038\/nature07737","volume":"458","author":"C Zhao","year":"2009","unstructured":"Zhao C, Chen A, Jamieson CH, Fereshteh M, Abrahamsson A, Blum J, et al. Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia. Nature. 2009;458:776\u20139.","journal-title":"Nature"},{"key":"3215_CR12","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1038\/leu.2011.55","volume":"25","author":"EK Allan","year":"2011","unstructured":"Allan EK, Holyoake TL, Craig AR, J\u00f8rgensen HG. Omacetaxine may have a role in chronic myeloid leukaemia eradication through downregulation of Mcl-1 and induction of apoptosis in stem\/progenitor cells. Leukemia. 2011;25:985\u201394.","journal-title":"Leukemia"},{"key":"3215_CR13","doi-asserted-by":"publisher","first-page":"355ra117","DOI":"10.1126\/scitranslmed.aag1180","volume":"8","author":"BZ Carter","year":"2016","unstructured":"Carter BZ, Mak PY, Mu H, Zhou H, Mak DH, Schober W, et al. Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cells. Sci Transl Med. 2016;8:355ra117.","journal-title":"Sci Transl Med"},{"key":"3215_CR14","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1038\/nm.4399","volume":"23","author":"EM Kuntz","year":"2017","unstructured":"Kuntz EM, Baquero P, Michie AM, Dunn K, Tardito S, Holyoake TL, et al. Targeting mitochondrial oxidative phosphorylation eradicates therapy-resistant chronic myeloid leukemia stem cells. Nat Med. 2017;23:1234\u201340.","journal-title":"Nat Med"},{"key":"3215_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-40222-z","volume":"14","author":"KM Rattigan","year":"2023","unstructured":"Rattigan KM, Brabcova Z, Sarnello D, Zarou MM. Pyruvate anaplerosis is a targetable vulnerability in persistent leukaemic stem cells. Nat Commun. 2023;14:4634.","journal-title":"Nat Commun"},{"key":"3215_CR16","doi-asserted-by":"publisher","DOI":"10.15252\/embr.202256279","volume":"24","author":"KM Rattigan","year":"2023","unstructured":"Rattigan KM, Zarou MM. Arginine dependency is a therapeutically exploitable vulnerability in chronic myeloid leukaemic stem cells. EMBO Rep. 2023;24:e56279.","journal-title":"EMBO Rep."},{"key":"3215_CR17","doi-asserted-by":"publisher","first-page":"3961","DOI":"10.1172\/JCI85239","volume":"126","author":"Y Jin","year":"2016","unstructured":"Jin Y, Zhou J, Xu F, Jin B, Cui L, Wang Y, et al. Targeting methyltransferase PRMT5 eliminates leukemia stem cells in chronic myelogenous leukemia. J Clin Invest. 2016;126:3961\u201380.","journal-title":"J Clin Invest"},{"key":"3215_CR18","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.ccr.2011.12.020","volume":"21","author":"L Li","year":"2012","unstructured":"Li L, Wang L, Li L, Wang Z, Ho Y, McDonald T, et al. Activation of p53 by SIRT1 inhibition enhances elimination of CML leukemia stem cells in combination with imatinib. Cancer Cell. 2012;21:266\u201381.","journal-title":"Cancer Cell"},{"key":"3215_CR19","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1016\/j.cmet.2022.04.004","volume":"34","author":"C Liu","year":"2022","unstructured":"Liu C, Zou W, Nie D, Li S, Duan C, Zhou M, et al. Loss of PRMT7 reprograms glycine metabolism to selectively eradicate leukemia stem cells in CML. Cell Metab. 2022;34:818\u2013835.e817.","journal-title":"Cell Metab"},{"key":"3215_CR20","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1158\/2159-8290.CD-15-1439","volume":"6","author":"H Xie","year":"2016","unstructured":"Xie H, Peng C, Huang J, Li BE, Kim W, Smith EC, et al. Chronic myelogenous leukemia-initiating cells require polycomb group protein EZH2. Cancer Discov. 2016;6:1237\u201347.","journal-title":"Cancer Discov"},{"key":"3215_CR21","doi-asserted-by":"publisher","first-page":"2634","DOI":"10.1038\/s41375-022-01682-2","volume":"36","author":"ED B\u00fchrer","year":"2022","unstructured":"B\u00fchrer ED, Amrein MA. Splenic red pulp macrophages provide a niche for CML stem cells and induce therapy resistance. Leukemia. 2022;36:2634\u201346.","journal-title":"Leukemia"},{"key":"3215_CR22","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1182\/blood-2023-182879","volume":"142","author":"M Dolinska","year":"2023","unstructured":"Dolinska M, Cai H. Characterization of the bone marrow niche in patients with chronic myeloid leukemia identifies CXCL14 as a new therapeutic option. Blood. 2023;142:73\u201389.","journal-title":"Blood"},{"key":"3215_CR23","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s40164-021-00233-2","volume":"10","author":"Y Yao","year":"2021","unstructured":"Yao Y, Li F, Huang J, Jin J, Wang H. Leukemia stem cell-bone marrow microenvironment interplay in acute myeloid leukemia development. Exp Hematol Oncol. 2021;10:39.","journal-title":"Exp Hematol Oncol"},{"key":"3215_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-021-01325-7","volume":"20","author":"J Mo","year":"2021","unstructured":"Mo J, Liang H, Su C, Li P, Chen J, Zhang B. DDX3X: structure, physiologic functions and cancer. Mol Cancer. 2021;20:38.","journal-title":"Mol Cancer"},{"key":"3215_CR25","doi-asserted-by":"publisher","first-page":"5336","DOI":"10.1093\/nar\/gkab287","volume":"49","author":"L Calviello","year":"2021","unstructured":"Calviello L, Venkataramanan S. DDX3 depletion represses translation of mRNAs with complex 5\u2032 UTRs. Nucleic Acids Res. 2021;49:5336\u201350.","journal-title":"Nucleic Acids Res."},{"key":"3215_CR26","doi-asserted-by":"publisher","first-page":"648","DOI":"10.15252\/emmm.201404368","volume":"7","author":"GM Bol","year":"2015","unstructured":"Bol GM, Vesuna F, Xie M, Zeng J, Aziz K, Gandhi N, et al. Targeting DDX3 with a small molecule inhibitor for lung cancer therapy. EMBO Mol Med. 2015;7:648\u201369.","journal-title":"EMBO Mol Med"},{"key":"3215_CR27","doi-asserted-by":"publisher","first-page":"3912","DOI":"10.1038\/onc.2008.33","volume":"27","author":"M Botlagunta","year":"2008","unstructured":"Botlagunta M, Vesuna F, Mironchik Y, Raman A, Lisok A, Winnard P Jr., et al. Oncogenic role of DDX3 in breast cancer biogenesis. Oncogene. 2008;27:3912\u201322.","journal-title":"Oncogene"},{"key":"3215_CR28","doi-asserted-by":"publisher","first-page":"2574","DOI":"10.1038\/onc.2015.336","volume":"35","author":"BA Wilky","year":"2016","unstructured":"Wilky BA, Kim C, McCarty G, Montgomery EA, Kammers K, DeVine LR, et al. RNA helicase DDX3: a novel therapeutic target in Ewing sarcoma. Oncogene. 2016;35:2574\u201383.","journal-title":"Oncogene"},{"key":"3215_CR29","doi-asserted-by":"publisher","first-page":"6340","DOI":"10.1158\/0008-5472.CAN-16-0440","volume":"76","author":"M Xie","year":"2016","unstructured":"Xie M, Vesuna F, Tantravedi S, Bol GM, Heerma van Voss MR, Nugent K, et al. RK-33 radiosensitizes prostate cancer cells by blocking the RNA helicase DDX3. Cancer Res. 2016;76:6340\u201350.","journal-title":"Cancer Res"},{"key":"3215_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41389-024-00509-2","volume":"13","author":"T Zhao","year":"2024","unstructured":"Zhao T, Zhu H, Zou T, Zhao S, Zhou L. DDX3X interacts with SIRT7 to promote PD-L1 expression to facilitate PDAC progression. Oncogenesis. 2024;13:8.","journal-title":"Oncogenesis"},{"key":"3215_CR31","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1007\/s00262-013-1467-x","volume":"62","author":"J Koshio","year":"2013","unstructured":"Koshio J, Kagamu H, Nozaki K, Saida Y, Tanaka T, Shoji S, et al. DEAD\/H (Asp-Glu-Ala-Asp\/His) box polypeptide 3, X-linked is an immunogenic target of cancer stem cells. Cancer Immunol Immunother. 2013;62:1619\u201328.","journal-title":"Cancer Immunol Immunother"},{"key":"3215_CR32","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s10495-020-01591-8","volume":"25","author":"O Shriwas","year":"2020","unstructured":"Shriwas O, Priyadarshini M, Samal SK, Rath R, Panda S, Das Majumdar SK, et al. DDX3 modulates cisplatin resistance in OSCC through ALKBH5-mediated m(6)A-demethylation of FOXM1 and NANOG. Apoptosis. 2020;25:233\u201346.","journal-title":"Apoptosis"},{"key":"3215_CR33","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s00439-011-1011-z","volume":"130","author":"JB Berletch","year":"2011","unstructured":"Berletch JB, Yang F, Xu J, Carrel L, Disteche CM. Genes that escape from X inactivation. Hum Genet. 2011;130:237\u201345.","journal-title":"Hum Genet"},{"key":"3215_CR34","first-page":"2905","volume":"25","author":"CY Chen","year":"2016","unstructured":"Chen CY, Chan CH, Chen CM, Tsai YS, Tsai TY, Wu Lee YH, et al. Targeted inactivation of murine Ddx3x: essential roles of Ddx3x in placentation and embryogenesis. Hum Mol Genet. 2016;25:2905\u201322.","journal-title":"Hum Mol Genet"},{"key":"3215_CR35","doi-asserted-by":"publisher","first-page":"4059","DOI":"10.1016\/j.molcel.2021.07.041","volume":"81","author":"C Gong","year":"2021","unstructured":"Gong C, Krupka JA, Gao J, Grigoropoulos NF, Giotopoulos G, Asby R, et al. Sequential inverse dysregulation of the RNA helicases DDX3X and DDX3Y facilitates MYC-driven lymphomagenesis. Mol Cell. 2021;81:4059\u20134075.e4011.","journal-title":"Mol Cell"},{"key":"3215_CR36","doi-asserted-by":"publisher","first-page":"2790","DOI":"10.1038\/onc.2014.190","volume":"34","author":"HH Chen","year":"2015","unstructured":"Chen HH, Yu HI, Cho WC, Tarn WY. DDX3 modulates cell adhesion and motility and cancer cell metastasis via Rac1-mediated signaling pathway. Oncogene. 2015;34:2790\u2013800.","journal-title":"Oncogene"},{"key":"3215_CR37","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.tranon.2018.09.002","volume":"12","author":"S Tantravedi","year":"2019","unstructured":"Tantravedi S, Vesuna F, Winnard PT Jr., Martin A, Lim M, Eberhart CG, et al. Targeting DDX3 in medulloblastoma using the small molecule inhibitor RK-33. Transl Oncol. 2019;12:96\u2013105.","journal-title":"Transl Oncol"},{"key":"3215_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.xpro.2023.102123","volume":"4","author":"C Liu","year":"2023","unstructured":"Liu C, Lin X, Jin Y, Pan J. Protocol for isolation and analysis of the leukemia stem cells in BCR-ABL-driven chronic myelogenous leukemia mice. STAR Protoc. 2023;4:102123.","journal-title":"STAR Protoc"},{"key":"3215_CR39","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.canlet.2019.04.003","volume":"454","author":"S Guo","year":"2019","unstructured":"Guo S, Ran H, Xiao D, Huang H, Mi L, Wang X, et al. NT5DC2 promotes tumorigenicity of glioma stem-like cells by upregulating fyn. Cancer Lett. 2019;454:98\u2013107.","journal-title":"Cancer Lett"},{"key":"3215_CR40","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.bbrc.2020.06.139","volume":"533","author":"X Jin","year":"2020","unstructured":"Jin X, Liu X, Zhang Z, Xu L. NT5DC2 suppression restrains progression towards metastasis of non-small-cell lung cancer through regulation p53 signaling. Biochem Biophys Res Commun. 2020;533:354\u201361.","journal-title":"Biochem Biophys Res Commun"},{"key":"3215_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-020-2549-2","volume":"11","author":"KS Li","year":"2020","unstructured":"Li KS, Zhu XD, Liu HD, Zhang SZ, Li XL, Xiao N, et al. NT5DC2 promotes tumor cell proliferation by stabilizing EGFR in hepatocellular carcinoma. Cell Death Dis. 2020;11:335.","journal-title":"Cell Death Dis"},{"key":"3215_CR42","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2022.1033684","volume":"10","author":"CS Ryan","year":"2022","unstructured":"Ryan CS, Schroder M. The human DEAD-box helicase DDX3X as a regulator of mRNA translation. Front Cell Dev Biol. 2022;10:1033684.","journal-title":"Front Cell Dev Biol"},{"key":"3215_CR43","first-page":"883","volume":"39","author":"Y He","year":"2018","unstructured":"He Y, Zhang D, Yang Y, Wang X, Zhao X, Zhang P, et al. A double-edged function of DDX3, as an oncogene or tumor suppressor, in cancer progression (Review). Oncol Rep. 2018;39:883\u201392.","journal-title":"Oncol Rep"},{"key":"3215_CR44","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1111\/odi.12076","volume":"20","author":"CH Lee","year":"2014","unstructured":"Lee CH, Lin SH, Yang SF, Yang SM, Chen MK, Lee H, et al. Low\/negative expression of DDX3 might predict poor prognosis in non-smoker patients with oral cancer. Oral Dis. 2014;20:76\u201383.","journal-title":"Oral Dis"},{"key":"3215_CR45","doi-asserted-by":"publisher","first-page":"18602","DOI":"10.18632\/oncotarget.4329","volume":"6","author":"CY Su","year":"2015","unstructured":"Su CY, Lin TC, Lin YF, Chen MH, Lee CH, Wang HY, et al. DDX3 as a strongest prognosis marker and its downregulation promotes metastasis in colorectal cancer. Oncotarget. 2015;6:18602\u201312.","journal-title":"Oncotarget"},{"key":"3215_CR46","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1158\/1078-0432.CCR-10-2316","volume":"17","author":"DW Wu","year":"2011","unstructured":"Wu DW, Liu WS, Wang J, Chen CY, Cheng YW, Lee H. Reduced p21(WAF1\/CIP1) via alteration of p53-DDX3 pathway is associated with poor relapse-free survival in early-stage human papillomavirus-associated lung cancer. Clin Cancer Res. 2011;17:1895\u2013905.","journal-title":"Clin Cancer Res"},{"key":"3215_CR47","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1038\/ng.3358","volume":"47","author":"L Jiang","year":"2015","unstructured":"Jiang L, Gu ZH, Yan ZX, Zhao X, Xie YY, Zhang ZG, et al. Exome sequencing identifies somatic mutations of DDX3X in natural killer\/T-cell lymphoma. Nat Genet. 2015;47:1061\u20136.","journal-title":"Nat Genet"},{"key":"3215_CR48","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1111\/bjh.13211","volume":"169","author":"J Ojha","year":"2015","unstructured":"Ojha J, Secreto CR, Rabe KG, Van Dyke DL, Kortum KM, Slager SL, et al. Identification of recurrent truncated DDX3X mutations in chronic lymphocytic leukaemia. Br J Haematol. 2015;169:445\u20138.","journal-title":"Br J Haematol"},{"key":"3215_CR49","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/nature11378","volume":"490","author":"R Schmitz","year":"2012","unstructured":"Schmitz R, Young RM, Ceribelli M, Jhavar S, Xiao W, Zhang M, et al. Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. Nature. 2012;490:116\u201320.","journal-title":"Nature"},{"key":"3215_CR50","doi-asserted-by":"publisher","first-page":"5444","DOI":"10.1128\/MCB.00560-10","volume":"30","author":"MC Lai","year":"2010","unstructured":"Lai MC, Chang WC, Shieh SY, Tarn WY. DDX3 regulates cell growth through translational control of cyclin E1. Mol Cell Biol. 2010;30:5444\u201353.","journal-title":"Mol Cell Biol"},{"key":"3215_CR51","doi-asserted-by":"publisher","first-page":"5976","DOI":"10.1111\/jcmm.16409","volume":"25","author":"B Hu","year":"2021","unstructured":"Hu B, Zhou S, Hu X, Zhang H, Lan X, Li M, et al. NT5DC2 promotes leiomyosarcoma tumour cell growth via stabilizing unpalmitoylated TEAD4 and generating a positive feedback loop. J Cell Mol Med. 2021;25:5976\u201387.","journal-title":"J Cell Mol Med"},{"key":"3215_CR52","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-29125-7","volume":"13","author":"H Han","year":"2022","unstructured":"Han H, Yang C. N(7)-methylguanosine tRNA modification promotes esophageal squamous cell carcinoma tumorigenesis via the RPTOR\/ULK1\/autophagy axis. Nat Commun. 2022;13:1478.","journal-title":"Nat Commun"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41388-024-03215-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-024-03215-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-024-03215-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T11:02:35Z","timestamp":1776942155000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41388-024-03215-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,8]]},"references-count":52,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,2,10]]}},"alternative-id":["3215"],"URL":"https:\/\/doi.org\/10.1038\/s41388-024-03215-w","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,8]]},"assertion":[{"value":"26 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All methods were performed in accordance with the relevant guidelines and regulations. This study involving patient samples was approved by the Jinan University Ethics Committee (JNUKY-2023-0063). Written informed consent was obtained from all CML patients. The animal experiments were performed with the approval of the Institutional Animal Care and Use Committee of South China University of Technology (2024108).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}